{"@type":"Dataset","integmet_study":"MTBLS354","mesh_chemical_id":["https://identifiers.org/mesh:D008055","https://identifiers.org/mesh:D008244","https://identifiers.org/mesh:D006028","https://identifiers.org/mesh:D014281","https://identifiers.org/mesh:D013109","https://identifiers.org/mesh:C008301"],"mesh_chemical_pubtator_kw":["lipid","Lipid","lysophosphatidylcholines","glycosphingolipids","trihexosylceramide","sphingomyelins","lysophosphatidylethanolamines"],"mesh_disease_id":["https://identifiers.org/mesh:D000092225","https://identifiers.org/mesh:D003147","https://identifiers.org/mesh:D007239","https://identifiers.org/mesh:D012141"],"mesh_disease_pubtator_kw":["extrapulmonary infection","community acquired pneumonia","infection","CAP","community-acquired pneumonia","respiratory tract infection"],"ncbi_taxonomy_id":["https://identifiers.org/taxonomy:9606"],"ncbi_taxonomy_pubtator_kw":["patients","patient"],"source_id":"https://identifiers.org/metabolights:MTBLS354","study_findings":"Lipid metabolites distinguish CAP cases; potential diagnostic and prognostic biomarkers.","study_observation":"Lipid metabolites in plasma samples from CAP and non-CAP patients.","study_summary":"Lipid metabolites as CAP biomarkers.","study_title_original":"Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia"}